Actively Recruiting
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Led by Assiut University · Updated on 2024-07-31
30
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.
CONDITIONS
Official Title
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 16 years or older
- Both genders are eligible
- Clinical diagnosis of Myasthenia Gravis confirmed by either clear response to pyridostigmine or a greater than 10% decrement in repetitive nerve stimulation study
- Willingness to undergo sample collection, imaging studies, and other disease-related assessments
You will not qualify if you...
- Younger than 16 years old
- History of chronic psychiatric or neurological disorders other than Myasthenia Gravis that cause weakness or fatigue
- Severe systemic illness affecting life expectancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Assiut University
Asyut, Egypt, 71515
Actively Recruiting
Research Team
N
Nourelhoda AA Haridy, Lecturer
CONTACT
E
Eman MH Khedr, Professor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here